Pharmaceutical Technology

AUGUST 23, 2022

It comprises messenger ribonucleic acid (mRNA) that encodes for the initial spike protein of SARS-CoV-2 along with mRNA that encodes for Omicron BA.4/BA.5 5 variant spike protein. According to pre-clinical findings, a booster dose of this vaccine elicited a robust neutralising antibody response against the variants Omicron BA.1,

Vaccination 130

Vaccination Vaccine Gene Therapy Protein 130

pharmaphorum

FEBRUARY 3, 2022

Al Sandrock’s shock departure from Biogen in November sparked speculation about where he would show up next, and the answer came in today – gene therapy specialist Voyager Therapeutics. The setbacks effectively sent Voyager back to being a preclinical-stage company however, setting it back years from bringing therapies to market.

Gene Therapy 97

Gene Therapy Gene Clinical Trials Clinical Trials 97

pharmaphorum

APRIL 21, 2022

The pharma company has decided to end its collaboration with Swedish biotech BioArctic on alpha-synuclein-targeting antibody ABBV-0805, which was in early-stage clinical testing, as well as a portfolio of follow-up antibodies. AZ/Takeda are meanwhile running phase 2 trials of their MEDI 1342 antibody candidate.

Antibody 97

Antibody Protein Gene Therapy Pharma Companies 97

Delveinsight

AUGUST 26, 2021

Shape Therapeutics inks gene therapy deal with Roche worth up to USD 3 Billion. Seattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Roche to bolster the development of gene therapies for Alzheimer’s and Parkinson’s disease.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

Delveinsight

DECEMBER 22, 2020

FDA Puts uniQure’s Hemophilia B Gene Therapy on Leash. In a recent, uniQure faced backlash after its hemophilia B gene therapy got hit with clinical hold by the USFDA. . The Hemophilia B market has several therapies, however, no therapy has been able to kill the disease from its root.

Gene Therapy 52

Gene Therapy Gene Trials Clinical Trials 52

XTalks

MAY 9, 2024

Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

Delveinsight

AUGUST 6, 2020

ZyCoV-D is designed to introduce DNA that encodes for a viral protein into human cells. By ordering human cells to make the protein, ZyCoV-D could cause an immune response against the coronavirus. Taysha raises USD 95 Million to take 4 CNS gene therapies into the clinic.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

The Pharma Data

JANUARY 9, 2021

(NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in any indication, with 134 participants.

Gene Therapy 52

Gene Therapy Gene Trials Clinical Trials 52

pharmaphorum

MARCH 9, 2022

Sanofi and Sobi’s haemophilia partnership has been under competitive pressure from new therapies like Roche’s antibody Hemlibra, so the two companies are hoping a new long-acting drug candidate can revitalise the franchise. The half life of the new drug – one of the main draws for Sanofi’s $11.6

Protein 98

Protein Gene Therapy Sales Regulation 98

pharmaphorum

MARCH 31, 2021

The diagnostic imaging agents all target fibroblast activation protein (FAP), a molecule that is only expressed at low levels on healthy cells but is found much more abundantly in solid tumours. billion to buy targeted radioligand therapy Lu-PSMA-617 from Endocyte , shortly after encouraging results in a phase 2 prostate cancer trial. .

Licensing 98

Licensing Licensing Gene Therapy Sales 98

pharmaphorum

AUGUST 17, 2020

BMS is best known as an early pioneer of checkpoint inhibitor therapies, which work by flipping a biochemical switch on tumour cells that suddenly makes them visible to the immune system, allowing T-cells to mount an attack. The companies hope that this will cause the area around the tumour to become inflammatory and begin to work against it.

Gene Therapy 59

Gene Therapy Clinical Trials Clinical Trials Gene 59

The Pharma Data

JULY 6, 2021

Data will include the final analysis from the phase IIIb STASEY study of Hemlibra® (emicizumab) and updated data from the phase I/II study of SPK-8011, an AAV-based gene therapy in development by Spark Therapeutics (a member of the Roche Group). Hemlibra is a bispecific factor IXa- and factor X-directed antibody.

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 7, 2021

To meet that goal, Sanofi is investing in areas like synthetic biology and cell and gene therapy. He also noted innovations are occurring with protein degraders, antibody conjugates, nanobodies and multi-specific antibodies, specifically bi- and tri-specific. billion acquisition of Synthorx.

Protein 52

Protein Antibody Genetics Gene Therapy 52

Delveinsight

AUGUST 20, 2020

FDA rejects BioMarin’s gene therapy and Gilead’s filgotinib over concerns. The FDA refused to approve BioMarin’s hemophilia A gene therapy valoctocogene roxaparvovec. a share in cash to get its hands on the anti-FcRn antibody, nipocalimab. The removal of an AdComm was seen as a positive.

Gene Therapy 52

Gene Therapy Research Gene Antibody 52

pharmaphorum

AUGUST 31, 2022

The marketing application comes on the back of data from the XTEND-1 trial in 159 patients with severe haemophilia A, which showed that efanesoctocog alfa was better at reducing the annualised rate of bleeding episodes than patients’ previous Factor VIII therapies, with the convenience of fewer infusions.

Drugs 52

Drugs Protein Marketing Gene Therapy 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT), today announced that the European Patent Office (EPO) has granted Patent # 3328401 , which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat oncology conditions. TEL AVIV, Israel, Oct. About VBL Vascular Biogenics Ltd.,

Antibody 40

Antibody Gene Therapy Containment Clinical Trials 40

The Pharma Data

DECEMBER 22, 2020

With these investments, EME plans to further promote its next-generation biotechnology-based drug discovery research and development focusing on heavy chain single domain antibodies, VHH. Comment from Fumiharu Muroga, Growth Manager at Real Tech Fund] “Proteins are an important structural component of living things.

Engineer 52

Engineer Drugs Protein Antibody 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH), a leading provider of proteins, antibodies and cytokines today announced that its Woburn, Massachusetts site received ISO 13485:2016 certification for Medical Device and Quality Management Systems. MINNEAPOLIS , Oct.

Manufacturing 40

Manufacturing Reagent Gene Therapy Protein 40

pharmaphorum

DECEMBER 1, 2022

Learn how to implement 3D Cell Culture techniques for antibody and cell and gene therapy discovery process. Academia – Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering. Featured Speakers Include: Stefan Przyborski, Professor Cell Technology, Durham University.

In-Vitro 52

In-Vitro Scientist Engineer Gene Therapy 52

pharmaphorum

MARCH 10, 2022

This trend will continue in the near future with a steady increase in market demand over the coming years, alongside further development in cell and gene therapies,” says Magnelli. Tapping into the momentum of biologics requires investment but identifying the right areas to invest in is a challenge in an evolving market.

Production 98

Production Life Science Development Gene Therapy 98

The Pharma Data

JUNE 7, 2023

Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service to accelerate programs from development to manufacturing, including fill/finish and packaging, and support for clinical supply and commercial launch.

Manufacturing 40

Manufacturing Development Protein Gene Therapy 40

pharmaphorum

JULY 11, 2022

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at the International Society on Thrombosis and Haemostasis (ISTH) congress over the weekend.

Engineer 52

Engineer Gene Therapy Sales Drugs 52

The Pharma Data

JANUARY 24, 2021

a company developing first-in-class therapeutic antibodies targeting the tumor microenvironment. Vickers has over 30 years of experience as a researcher and leader in the pharmaceutical industry. He most recently served as president and CEO of Northern Biologics, Inc., He earned his B.Sc.

Medicine 52

Medicine Pharma Companies Gene Therapy Development 52

XTalks

JUNE 4, 2024

Targeting B Cell-Driven Autoimmunity The company’s focus on diseases such as lupus nephritis, multiple sclerosis and myasthenia gravis is driven by the recognition that B cells, a subset of lymphocytes responsible for antibody production, play a pivotal role in these conditions.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Antibody 52

Roots Analysis

AUGUST 8, 2023

Disposable bioreactors have transformed the process of conventional biomanufacturing, and their adoption is increasing rapidly for production of various biologics, such as antibody, recombinant proteins, cell and gene therapy.

Manufacturing 52

Manufacturing Production Marketing Gene Therapy 52

XTalks

NOVEMBER 1, 2024

Price of Ocrevus: $78,858 annually Why it sold so well: Ocrevus is a therapeutic monoclonal antibody that offers a unique scientific approach to treating MS. This condition results from these mutations, which lead to inadequate SMN protein expression. Price of Zolgensma: Zolgensma has a price of $2.1

FDA Approval 85

FDA Approval Drugs Botox Sales 85

Roots Analysis

AUGUST 29, 2023

In this context, it is worth highlighting those 14 biopharmaceutical products ( including cell therapies, gene therapies, monoclonal antibodies and recombinant proteins ) were approved in the US alone, in 2021. For instance, in 2021, a sum of over USD 70 billion was invested in the cell and gene therapy domain.

Contract Manufacturing 40

Contract Manufacturing Manufacturing Gene Therapy Marketing 40

Roots Analysis

AUGUST 29, 2023

In this context, it is worth highlighting those 14 biopharmaceutical products ( including cell therapies, gene therapies, monoclonal antibodies and recombinant proteins ) were approved in the US alone, in 2021. For instance, in 2021, a sum of over USD 70 billion was invested in the cell and gene therapy domain.

Contract Manufacturing 40

Contract Manufacturing Manufacturing Gene Therapy Marketing 40

XTalks

AUGUST 30, 2022

We know that a lot of different pathologies, especially as we’ve entered the era of molecular medicine and gene therapies, cause many of the same symptoms and work through final common pathways. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets? Next Steps for Targeted CNS Delivery.

Trials 83

Trials Drug Delivery Drugs Gene 83

Roots Analysis

APRIL 15, 2024

These complex entities, such as antibodies, antibody drug conjugates, cell therapies, gene therapies, and therapeutic proteins, are highly specific molecules that are designed to precisely target biomarkers associated with a particular disease pathway.

Manufacturing 40

Manufacturing Production Contract Manufacturing Contamination 40

The Pharma Data

JUNE 26, 2021

4 Ranibizumab is a vascular endothelial growth factor (VEGF) inhibitor designed to bind to and inhibit VEGF-A, a protein that is believed to play a critical role in the formation of new blood vessels and the leakiness of the vessels. Faricimab is the first investigational bispecific antibody designed for the eye.

Drug Delivery 52

Drug Delivery Clinical Trials Clinical Trials Medicine 52

XTalks

DECEMBER 8, 2020

has announced that it has acquired the rights to an investigational gene therapy, HMR59, from Hemera Biosciences, LLC designed to help treat a severe form of age-related macular degeneration (AMD). The gene therapy was developed to treat both dry and wet macular degeneration. Janssen Pharmaceuticals Inc.

Gene Therapy 98

Gene Therapy Gene Protein Development 98

XTalks

JUNE 28, 2023

Gene therapies for Duchenne muscular dystrophy (DMD) have been an area of intense research and Sarepta’s Elevidys is now the first one to be approved by the US Food and Drug Administration (FDA). DMD is caused by the absence of dystrophin, a protein that helps maintain the integrity of muscle cells.

Gene Therapy 98

Gene Therapy Gene Protein FDA Approval 98

XTalks

APRIL 12, 2021

Like other neurodegenerative disorders, such as Alzheimer’s disease and dementias, Parkinson’s disease research has been immensely challenging for biotechs, with a high rate of late-stage attrition in trials leading to a lack of disease-modifying therapies being approved. Axovant Gene Therapies. Prevail Therapeutics.

Gene Therapy 96

Gene Therapy Gene Trials Development 96

Pfizer

SEPTEMBER 28, 2022

Monovalent refers to any authorized and approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2 virus . Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A Has Re-Opened Recruitment. COMIRNATY® (COVID-19 Vaccine, mRNA) INDICATION.

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

XTalks

JANUARY 4, 2024

Pfizer has kickstarted the new year with its first-ever gene therapy approval, awarded by Health Canada to the company’s Beqvez (fidanacogene elaparvovec) for the treatment of hemophilia B. Treatment involves replacing the missing FIX clotting protein, traditionally through regular infusions.

Gene Therapy 111

Gene Therapy Gene Gene Editing Sales 111

Delveinsight

DECEMBER 3, 2020

Roche receives FDA authorization for the quantitative COVID-19 antibody test. Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies, which target the cell-unlocking spike protein of coronavirus. Janssen buys a gene therapy asset.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52